BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abilify aripiprazole neurology data

The U.S. Department of Health and Human Service's Agency for Healthcare Research and Quality (AHRQ) released a comparative effectiveness review of therapies for children ages 2-12 with autism spectrum disorders. The report found that the atypical antipsychotics Abilify aripiprazole and Risperdal risperidone showed benefit...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >